The Truth About Tamiflu - The Atlantic (December 10, 2009)

Two months ago, we pointed out in our story on flu in The Atlantic that the
antiviral drug Tamiflu might not be as effective or safe as many patients,
doctors, and governments think. The drug has been widely prescribed since the first cases of H1N1 flu surfaced last spring, and the U.S. government has spent more than
$1.5 billion stockpiling it since 2005 as part of the nation’s pandemic preparedness
plan.

Now it looks as if our concerns were correct, and the nation may have put more than
a billion dollars into the medical equivalent of a mirage. This week, the British
medical journal BMJ published a multi-part investigation that confirms that the
scientific evidence just isn't there to show that Tamiflu prevents serious
complications, hospitalization, or death in people that have the flu. The BMJ goes
further to suggest that Roche, the Swiss company that manufactures and markets
Tamiflu, may have misled governments and physicians. In its defense, Roche stated
that the company “has never concealed (or had the intention to conceal) any
pertinent data.

To read the article in its entirety continue here.